Novo Nordisk AS (BSP:N1VO34) Total Payout Ratio : 0.70 (As of Dec. 12, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk AS Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Novo Nordisk AS's current Total Payout Ratio is 0.70.

Novo Nordisk AS Total Payout Ratio Historical Data

The historical data trend for Novo Nordisk AS's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Total Payout Ratio Chart

Novo Nordisk AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

Get a 7-Day Free Trial

0.89

0.88

0.86

0.89

0.74

Novo Nordisk AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Payout Ratio	Get a 7-Day Free Trial															0.87	0.44	1.24	0.37	0.66

Competitive Comparison of Novo Nordisk AS's Total Payout Ratio

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS's Total Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Total Payout Ratio falls into.

Novo Nordisk AS Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Novo Nordisk AS's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-21452.217	+	0	+	-22773.446)	/	59991.509
	=	0.74

Novo Nordisk AS's Total Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-1982.496	+	0	+	-12845.421)	/	22504.834
	=	0.66

Novo Nordisk AS Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (BSP:N1VO34) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines